GMDA News and Press, Gamida Cell Ltd. From 03/21/19

– Shawn Cline Tomasello and Stephen T. Wills bring extensive experience in building successful commercial-stage life sciences companies – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline...

Gamida ( GMDA ) is a small, pivotal stage Israeli company developing Nicotinamide-enhanced cell therapies targeting a number of cancers. The clinical proposition is interesting: The company is using its technology to improve the prospects of hematopoietic stem cell transfer or HSCT, which is c...

Gamida Cell (NASDAQ: GMDA ): FY GAAP EPS of -$10.53. More news on: Gamida Cell, Earnings news and commentary, Healthcare stocks news, Read more ...

– Successfully Completed IPO Raising $53.2 Million in Gross Proceeds – – Patient Enrollment in Phase 3 Study of NiCord ® on Track for Completion in Second Half of 2019; Topline Results Expected in First Half of 2020 – – Recently Present...

– Data support ongoing Phase 3 study of NiCord in patients with hematologic malignancies – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that translational data from the completed Phase 1/2 clinical study of NiCord...

– NAM-NK therapy clinically active and generally well tolerated, with multiple complete responses observed – – Data in severe aplastic anemia support potential of NiCord to treat non-malignant bone marrow failure disorders – – Gamida Cell to host...

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natura...

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that it will host a conference call and webcast on Thursday, February 21, 2019, at 8:00 a.m. ET to review the data from its NAM-NK and NiCord ® programs being presented at the 2019 Tr...

Shares of small Israeli biotech firm Gamida Cell ( GMDA ) have performed admirably out of the gate, rising over 60% so far since its October IPO . One telling sign that this one could do well was the fact that insiders (Novartis and Cial Biotechnology) chose to purchase $37.5 million out of...